Nasus Pharma (NSRX) Cash from Discontinued Operations (2024)
Nasus Pharma's (NSRX) quarterly Cash from Discontinued Operations came in at 7000.0 in Q4 2024.
Nasus Pharma (NSRX) Cash from Discontinued Operations (2024) Analysis & Trends
Nasus Pharma (NSRX) has 1 years of Cash from Discontinued Operations data on file, last reported at 7000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.61 Bn |
| 10 | Nasus Pharma | 32.04 Mn | 32.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -7,000.00 |
| Dec 31, 2024 | -7,000.00 |